Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4742746 | 0.76 | — | — | |
| SCHEMBL22392302 | 0.73 | — | — | |
| SCHEMBL17890966 | 0.70 | — | — | |
| SCHEMBL17891254 | 0.68 | — | — | |
| SCHEMBL17891202 | 0.65 | — | — | |
| SCHEMBL379296 | 0.65 | PARL (0.34) | KMT2AATM | |
| SCHEMBL230241 | 0.65 | PARL (0.34) | KMT2AATM | |
| SCHEMBL21709762 | 0.63 | — | — | |
| SCHEMBL17891130 | 0.62 | — | — | |
| SCHEMBL8560241 | 0.62 | LMNA (0.32) | KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2024-04-11 | — | — | US | disclosed |
| US-11903994-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-11844841-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230091471-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2023-03-23 | — | — | US | disclosed |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11338013-B2 | Combination therapy for C3 inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210401997-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2021-12-30 | — | — | US | disclosed |
| US-11040107-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210032289-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2021-02-04 | — | — | US | disclosed |
| US-10875893-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200325175-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2020-10-15 | — | — | US | disclosed |
| US-20200316163-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | JPHARMA SOLUTIONS GMBH (CH) | 2020-10-08 | — | — | US | disclosed |
| US-20200282012-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200038516-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20190194254-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2019-06-27 | — | — | US | disclosed |
| US-10035822-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170283461-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20160215020-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160194359-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040107-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | KMT2A 4187/4885ATM 2403/4885 |
| US-20190194254-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | KMT2A 4120/4885ATM 2414/4885 |
| US-20200282012-A1 | COMBINATION THERAPY FOR C3 INHIBITION | C3AR1, C5, CFH | KMT2A 3072/4885ATM 2377/4885 |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | C3AR1, C5, CFH | KMT2A 3072/4885ATM 2377/4885 |
| US-20160215020-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | KMT2A 4120/4885ATM 2414/4885 |
| US-10875893-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | ANPEP, APLNR, CTSC | KMT2A 669/4885ATM 3120/4885 |
| US-20170283461-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | KMT2A 4118/4885ATM 2410/4885 |
| US-11844841-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | KMT2A 4187/4885ATM 2403/4885 |
| US-11903994-B2 | Dosing regimens | C3AR1, C1QBP, C9 | KMT2A 4125/4885ATM 2671/4885 |
| US-20160194359-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | KMT2A 4118/4885ATM 2410/4885 |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | KMT2A 4187/4885ATM 2403/4885 |
| US-20230091471-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | KMT2A 4120/4885ATM 2414/4885 |
| US-10035822-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | ANPEP, LNPEP, ENPEP | KMT2A 1555/4885ATM 3745/4885 |
| US-20210032289-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | KMT2A 4120/4885ATM 2414/4885 |
| US-20200316163-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | KMT2A 4187/4885ATM 2403/4885 |
| US-20210401997-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | KMT2A 4187/4885ATM 2403/4885 |
| US-11338013-B2 | Combination therapy for C3 inhibition | C3AR1, C5, CFH | KMT2A 3072/4885ATM 2377/4885 |
| US-20200038516-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | KMT2A 4187/4885ATM 2403/4885 |
| US-20200325175-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | KMT2A 4118/4885ATM 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.